A Phase II clinical trial involving 23 ALS patients receiving rasagiline (2 mg/day) showed increased ΔΨm and oxygen radical antioxidant capacity (ORAC) in lymphocytes and a decrease in the apoptotic marker Bcl-2/Bax ratio [428]. The gene discussed is BCL2; the disease is amyotrophic lateral sclerosis.